Fractyl Laboratories said today that a clinical trial of its Revita DMR therapy for patients with Type 2 diabetes with and without nonalcoholic fatty liver disease (NAFLD) has produced positive results. The Revita-2 trial was a randomized, double-blind, sham-controlled, multicentered study that showed the therapy is safe and effective relative to a sham procedure. Lexington, […]
Fractyl Laboratories
These medtech companies raised the most VC last year
Perhaps there’s a ray of hope that venture capital funding is recovering a bit for the medical device industry. VC firms invested more than $2.8 billion in 2017, an increase of more than $647 million from 2016, according to the MoneyTree Report from PricewaterhouseCoopers (PwC) and CB Insights. There were a total 229 deals involving […]
Tandem’s finance chief to retire at year’s end | Personnel Moves – Dec. 8, 2017
Tandem Diabetes Care (NSDQ:TNDM) announced today that its EVP and chief financial exec, John Cajigas, will retire at the end of 2017. The company’s SVP of finance, Leigh Vosseller, is slated to take his place effective Jan. 1. Tandem noted that Cajigas’ retirement is not due to any disagreement or problem with the company’s accounting or […]
Fractyl raises $44m Series D for Revita DMR tech
Fractyl Laboratories said today that it raised $44 million in a Series D round, led by an undisclosed investor and first-time investors GV, True Ventures and the IDO Fund. Returning investors included Deerfield Management Company, Bessemer Venture Partners and others. The company said it plans to use the round’s proceeds to fund the continued development of […]
Fractyl Labs touts 1-year data for Revita DMR in T2D patients
Fractyl Laboratories touted data today showing sustained improvement in glycemic parameters after one year following a single treatment with its Revita duodenal mucosal resurfacing system in patients with Type II diabetes. “This is the first presentation of one-year data on the durability of the Revita DMR procedure in Type II diabetes. The Revita DMR procedure was […]
Fractyl Labs launches Revita DMR diabetic treatment study
Fractyl Laboratories said today it launched the Revita-2 clinical trial of its Revita DMR procedure in orally-treated type 2 diabetes patients with poorly controlled disease. The company said that it has enrolled the 1st patient in the trial at a European center participating in the study. The Revita DMR is a minimally invasive procedure designed to […]
Fractyl eyes insulin resistance in fatty liver disease
Fractyl Laboratories presented data last week at the annual meeting of the American Assn. for the Study of Liver Diseases, touting its Revita duodenum mucosal resurfacing device in patients with metabolic diseases driven by insulin resistance, such as Type II diabetes and fatty liver disease. The Lexington, Mass.-based company’s Revita DMR trans-oral procedure targets a part of the intestine called the duodenum. The duodenum […]
Fractyl touts 1st-in-human data, grabs ex-GI Dynamics medical chief Maggs
Fractyl Laboratories today touted the publication of 1st-in-human data from a trial of its Revita duodenal mucosal resurfacing device and said it picked up former GI Dynamics (ASX:GID) medical chief Dr. David Maggs, who was fired last June, as its new chief medical officer. Results from the study were published in Diabetes Care this month, […]
Ethicon study reports bariatric surgery as effective treatment for Asian Indian type II patients | American Diabetes Assn. 2016 Scientific Sessions
Ethicon study reports bariatric surgery as effective treatment for Asian Indian type II patients Johnson & Johnson (NYSE:JNJ) subsidiary Ethicon said it presented data from a study supporting bariatric surgery as a better treatment option than medical therapy and lifestyle management for obese Asian Indian patients with inadequately controlled type 2 diabetes. Data came from […]
Diabetes: Fractyl Labs closes $57m Series C round
Fractyl Laboratories said today that it closed a Series C round worth $57 million with a final, $17 million tranche joined by new backer Deerfield Management, as it readies its Retiva device for a Phase II trial. Waltham, Mass.-based Fractyl calls the Retiva a “duodenal mucosal resurfacing” device; it’s designed to separate the mucosa and sub-mucosa […]
